Skip to content

Author

Li-Yuan Zhao

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

A small molecule ACT004 targets four-and-a-half LIM domain protein 1 to disrupt TGF-β/Smad signaling and promote FHL1 degradation in renal fibrosis.

Renal fibrosis is a common endpoint of chronic kidney disease (CKD), yet effective targeted anti-fibrotic therapies remain limited. Ovatodiolide (OVA) has anti-fibrotic activity but poor drug-like properties, whereas ACT004, a synthetic OVA derivative, has improved water solubility and metabolic stability. However, whe...

Xiao-Yang He, Fen-Fen Peng, Hui-Zhen Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.